Delivery Matters: In Early Studies, DPX Technology Allows Vaccines to Persist When Cancer Pushes Back

Based on promising results, the biotech IMV has moved into phase 2b trials with a cancer vaccine composed of survivin epitopes that uses the company’s proprietary delivery system to elicit persistent immune responses.

Related Keywords

New York ,United States ,Stonegate ,American ,Andrew Hall ,Jeremy Graff ,Cargo In Oil ,American Society Of Hematology Annual Meeting ,That Persist ,Evidence Based Oncology ,American Society ,Hematology Annual Meeting ,Accessed March ,Dpx ,Cancer Vaccines ,Immuno Oncology ,Immunotherapy ,